- - Total revenue from sales & service 770.1 686.0 12.3% 771.8 -0.2% Cost of sales 349.1 322.2 8.3% 355.1 -1.7% Gross profit 421.0 363.8 15.7% 416.7 1.0% % 54.7% 53.0% 54.0% Other Income 4.3 3.6 21.2% 3.5
information in the consolidated financial statements. 5 Financial Ratios Gross Profit margin = Gross Profit (Total Sales – Costs of Sales) to Sales Net Profit margin = Net Profit to Total Revenues Debt to
MTHB * Note Please find further information in the consolidated financial statements. 6 Financial Ratios Gross Profit margin = Gross Profit (Total Sales – Costs of Sales) to Sales Net Profit margin = Net
profit margin 2.70% 46.22% (43.52%) DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 2 * Note the financial statements for the 3rd quarter ended
No: AH 02022024 February 29th, 2024 Subject: Management Discussion & Analysis (MD&A) for the financial statements of fiscal year 2023 ended as of December 31, 2023 To: The President The Stock Exchange
increase 202% from 1H2016 result. 1. RESULTS OF OPERATION FOR 2Q2017 Consolidated Financial Statements 2Q2016 2Q2017 Increase/(Decrease) Baht million Baht million Baht million % Revenue from Sales and
as below: From the Consolidated Financial Statements for the second quarter of 2020, for the three-month period ended June 30, 2020, the Company has operating profit amount of THB 7.25 million, a
1 Ref: CIG 037/2017 August 15, 2017 Subject: Profit and loss reporting for the second quarter of 2017 and explanation of more than 20 percent fluctuation in profit and loss compared to that of last
consolidated financial statements for the third quarter of the year 2017, ended September 30, 2017, that have been accordingly reviewed by the Company’s external auditor and by the Audit Committee at the meeting